Detail Information of Xenobiotics

General Information of Xenobiotics (ID: XEO00579)
Xenobiotics Name
SGX301
Xenobiotics Type
Pharmaceutical Agent(s)
Classification
Drug in Phase 3 Clinical Trial
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=3663"></iframe>
3D MOL 2D MOL
PubChem CID
3663
DME(s) Modulated by This Xenobiotics
DME(s) Inhibited by This Xenobiotics
Cytochrome P450 1A1 (CYP1A1) DME Info Homo sapiens [1]
Cytochrome P450 3A4 (CYP3A4) DME Info Homo sapiens [2]
Unclear metabolic mechanism (DME-unclear) DME Info Streptococcus mutans [3]
Glutathione S-transferase alpha-1 (GSTA1) DME Info Homo sapiens [4]
Glutathione S-transferase pi (GSTP1) DME Info Homo sapiens [4]
Glutamate racemase (MurI) DME Info Streptococcus mutans [3]
References
1 StJohn's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1. Cancer Res. 2003 Nov 15;63(22):8062-8.
2 In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther. 2004 Jul-Aug;11(4):262-77.
3 In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones. Antimicrob Agents Chemother. 2007 Apr;51(4):1541-4.
4 A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.